Limited Cerebral Metastases in NSCLC: A Literature Review of SRS Versus Whole-brain Radiotherapy

Overview

Journal Cancer Diagn Progn

Specialty Oncology

Date 2022 Nov 7

PMID 36340461

Authors

Maria Grenzelia

Anna Zygogianni

Dimitra Grapsa

Emmanouil Maragkoudakis

Eleni Fyta

Andrianni Charpidou

Konstantinos Syrigos

Petros Mpakakos

Affiliations

Soon will be listed here.

Abstract

Background/aim: Brain metastases (BMs) are common in patients with non-small cell lung cancer (NSCLC). Whole-brain radiotherapy (WBRT) with or without corticosteroid use has historically been the first choice for most patients with BMs despite its negative impact on cognition and quality of life. However, stereotactic radiosurgery (SRS) has emerged as a safe and effective treatment and has been established for patients with limited, inoperable BMs. SRS and WBRT are either used separately or together, in an attempt to achieve the best possible local and distal control rates and even improve overall survival. A number of phase III trials have focused on answering the question which modality - SRS, WBRT or both - can achieve the best possible results. In this review, we present the existing data regarding the use of SRS compared with WBRT and their combination for NSCLC patients with limited, non-operable BMs.

Materials And Methods: A literature review was performed in PubMed, Medline, and the Cochrane Library databases from 1995 up to 2021. Principles outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement were followed.

Results: We identified seven randomised control trials (RCTs) that compared WBRT with WBRT plus SRS boost and four RCTs that compared SRS alone with SRS plus WBRT.

Conclusion: Overall, addition of WBRT to SRS did not improve survival but had a positive effect on locoregional control.

References

Churilla T, Ballman K, Brown P, Twohy E, Jaeckle K, Farace E . Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial. Int J Radiat Oncol Biol Phys. 2017; 99(5):1173-1178. PMC: 5699951. DOI: 10.1016/j.ijrobp.2017.07.045. View

Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K . Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006; 295(21):2483-91. DOI: 10.1001/jama.295.21.2483. View

Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T . Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997; 37(4):745-51. DOI: 10.1016/s0360-3016(96)00619-0. View

Langer C, Mehta M . Current management of brain metastases, with a focus on systemic options. J Clin Oncol. 2005; 23(25):6207-19. DOI: 10.1200/JCO.2005.03.145. View

Gulbas H, Erkal H, Serin M . The use of recursive partitioning analysis grouping in patients with brain metastases from non-small-cell lung cancer. Jpn J Clin Oncol. 2006; 36(4):193-6. DOI: 10.1093/jjco/hyl007. View

Weitzner M, Meyers C, Gelke C, Byrne K, Cella D, Levin V . The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer. 1995; 75(5):1151-61. DOI: 10.1002/1097-0142(19950301)75:5<1151::aid-cncr2820750515>3.0.co;2-q. View

Aoyama H, Tago M, Shirato H . Stereotactic Radiosurgery With or Without Whole-Brain Radiotherapy for Brain Metastases: Secondary Analysis of the JROSG 99-1 Randomized Clinical Trial. JAMA Oncol. 2015; 1(4):457-64. DOI: 10.1001/jamaoncol.2015.1145. View

Alexander B, Brown P, Ahluwalia M, Aoyama H, Baumert B, Chang S . Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol. 2018; 19(1):e33-e42. DOI: 10.1016/S1470-2045(17)30692-7. View

Aoyama H, Tago M, Kato N, Toyoda T, Kenjyo M, Hirota S . Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys. 2007; 68(5):1388-95. DOI: 10.1016/j.ijrobp.2007.03.048. View

10.

Gaspar L, Scott C, Murray K, Curran W . Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys. 2000; 47(4):1001-6. DOI: 10.1016/s0360-3016(00)00547-2. View

11.

El Gantery M, Abd El Baky H, El Hossieny H, Mahmoud M, Youssef O . Management of brain metastases with stereotactic radiosurgery alone versus whole brain irradiation alone versus both. Radiat Oncol. 2014; 9:116. PMC: 4035803. DOI: 10.1186/1748-717X-9-116. View

12.

Soffietti R, Kocher M, Abacioglu U, Villa S, Fauchon F, Baumert B . A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery:.... J Clin Oncol. 2012; 31(1):65-72. DOI: 10.1200/JCO.2011.41.0639. View

13.

Noyama T, Katano A, Shinya Y, Kawashima M, Shin M, Saito N . Prognostic Factors for Patients With Brain Metastases Treated With Single-fraction Gamma Knife Radiosurgery. Anticancer Res. 2021; 41(6):3179-3185. DOI: 10.21873/anticanres.15104. View

14.

Sperduto P, Chao S, Sneed P, Luo X, Suh J, Roberge D . Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2009; 77(3):655-61. DOI: 10.1016/j.ijrobp.2009.08.025. View

15.

Jablonska P, Bosch-Barrera J, Serrano D, Valiente M, Calvo A, Aristu J . Challenges and Novel Opportunities of Radiation Therapy for Brain Metastases in Non-Small Cell Lung Cancer. Cancers (Basel). 2021; 13(9). PMC: 8124815. DOI: 10.3390/cancers13092141. View

16.

Chao S, de Salles A, Hayashi M, Levivier M, Ma L, Martinez R . Stereotactic Radiosurgery in the Management of Limited (1-4) Brain Metasteses: Systematic Review and International Stereotactic Radiosurgery Society Practice Guideline. Neurosurgery. 2017; 83(3):345-353. DOI: 10.1093/neuros/nyx522. View

17.

Chang E, Wefel J, Hess K, Allen P, Lang F, Kornguth D . Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009; 10(11):1037-44. DOI: 10.1016/S1470-2045(09)70263-3. View

18.

Venur V, Ahluwalia M . Prognostic scores for brain metastasis patients: use in clinical practice and trial design. Chin Clin Oncol. 2015; 4(2):18. DOI: 10.3978/j.issn.2304-3865.2015.06.01. View

19.

Brown P, Jaeckle K, Ballman K, Farace E, Cerhan J, Anderson S . Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. JAMA. 2016; 316(4):401-409. PMC: 5313044. DOI: 10.1001/jama.2016.9839. View

20.

Louie A, Rodrigues G, Yaremko B, Yu E, Dar A, Dingle B . Management and prognosis in synchronous solitary resected brain metastasis from non-small-cell lung cancer. Clin Lung Cancer. 2009; 10(3):174-9. DOI: 10.3816/CLC.2009.n.024. View